Prof. John Deanfield states that the introduction of two new drug classes with CV benefits can really make a difference for the CV outcomes of high-risk diabetic patients
ESC 2017 Prof. Galiè summarizes new results regarding pulmonary hypertension (PH) that were presented at ESC 2017, separately for each clinical PH group. Treatment options expand and some can improve patient outcomes.
Prof. Lars Rydén describes two classes of drugs that may protect patients with type 2 diabetes from CV events. Depending on the type of patient, cardiologists can choose a drug.
ESC 2017 Dr. Wilko Spiering summarises the results of the CALM-FIM study, showing that endovascular baroreflex amplification with MobiusHD device lowers BP in resistant hypertension.
ESC 2017 Clyde Yancy summarises insights of studies presented at the ESC on managment of hypertension and associated CV risk, which can help understanding of how treatment can be improved.
Inflammation Expert Opinions Lina Badimon explains why blocking inflammation may have significant clinical benefit, as inflammation is important in plaque formation. The results of CANTOS can be the dawn of a new era of CV prevention.
ESC 2017 A patient-level pooled analysis of REMINDER and ALBATROSS data suggests that there may be a mortality benefit of treating STEMI patients with a mineralocorticoid receptor antagonist.
Inflammation Expert Opinions Erik Stroes summarizes the results from CANTOS and states that for daily clinical practice, it is important to select the major factors contributing to CV risk
Inflammation Expert Opinions Filippo Crea riflette su una pubblicazione del 1994, introducendo l’ ipotesi sull’infiammazione e spiega come lo studio CANTOS confermi tale ipotesi. La sfida ora è individuare i pazienti che trarranno beneficio da questo trattamento.
ESC 2017 Dr. Christie Ballantyne summarises results of diverse studies into various lipid lowering therapies, both approved and experimental strategies, and concludes that they all reinforce current guidelines.
ESC 2017 Virtual histology of components of plaque does not provide additional information in the serial imaging GLAGOV study that showed more coronary atherosclerosis regression when evolocumab was added to intensive statin-treatment.
Inflammation Expert Opinions Paul Ridker and Peter Libby look back at the evolution of their research efforts on the role of inflammation in CV risk, and how they saw their hypothesis confirmed in the CANTOS trial.